fda glp-1 warning letters october 2025 Beyond the Headlines: FDA Warning Letters to GLP-1 Compounders

Week Ending October 31, 2025: Featuring a Panel of FDA Compliance Leaders Discussing Key Current Concerns

25.33

★★★★☆4.8 (126)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

23.74

★★★★★4.9 (98)

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

23.97

★★★★★5.0 (157)

The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed 'fastest growing company in history.'

26.97

★★★★★4.7 (84)

September 8, 2025: FDA launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines

20.39

★★★★★4.9 (203)

Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s

22.68

★★★★★5.0 (176)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or

25.21

★★★★★4.8 (132)